Abcam, ab250814, Anti-Factor XIII antibody [EPR10986(2)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Factor XIII antibody. Carrier free. Suitable for IP, WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR10986(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250814 is the carrier-free version of
ab185215
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Factor XIII also known as fibrin-stabilizing factor is an enzyme that plays a role in blood coagulation. It is a zymogen of approximately 320 kDa expressed primarily in the liver megakaryocytes and placenta. In its active form Factor XIII is a heterotetramer composed of two A subunits and two B subunits. The A subunits are the catalytic parts while the B subunits function as carriers. Factor XIII is widely present in plasma and in platelets aiding in clot stabilization.
Biological function summary
Factor XIII acts to strengthen and stabilize the fibrin clot by cross-linking fibrin molecules. The enzyme is part of a larger complex known as the blood coagulation pathway. Factor XIII becomes activated by thrombin in the presence of calcium ions. Upon activation it catalyzes the formation of covalent bonds between fibrin molecules enhancing the mechanical strength and resistance of the blood clot. This action prevents premature clot lysis and supports wound healing.
Pathways
Factor XIII plays a significant role in the coagulation cascade and fibrinolytic system. In the coagulation pathway it functions downstream of fibrin formation providing cross-linking important to clot integrity. Factor XIII is closely associated with proteins such as fibrinogen and thrombin which are key components in the clotting process. Additionally Factor XIII interacts with the fibrinolytic system connecting to proteins like plasmin that are essential for clot breakdown.
Malfunction or deficiency of Factor XIII can lead to bleeding disorders such as Factor XIII deficiency characterized by a tendency to bleed excessively. This deficiency severely impacts the stabilization of clots resulting in poor wound healing. Additionally abnormal Factor XIII activity can contribute to thrombotic disorders where excessive clot stabilization occurs linking Factor XIII to proteins involved in thrombus formation like fibrin and plasminogen. Understanding these interactions is key in managing related conditions.